Irinotecan in the management of patients with pancreatic cancer

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 14, 2000, Pages 31-33

  Green, Mark R ^a   Harper, Melinda ^b   Safa, Ahmad ^a   Sherman, Carol A ^a   Mushtaq, Chaudry M ^a   Bahadori, Hamid ^a   Brescia, Frank J ^a   Rocha Lima, Caio M S P ^c  

^a Department of Medicine ^*

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN;

HUMAN; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; COMBINED MODALITY THERAPY; HUMANS; MULTICENTER STUDIES; PANCREATIC NEOPLASMS;

EID: 0034564489     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Greenlee RT, Murray T, Bolden S, et al: Cancer statistics 2000. CA Cancer J Clin 50:7-33, 2000.
2. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1999. CA Cancer J Clin 49:8-31, 1999.
3. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 49:33-64, 1999.
4. Glimelius B, Huffman K, Sjöden PO, et al: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593-600, 1996.
5. Schnall SF, MacDonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23: 220-228, 1996.
6. Burris HA III, Moore MJ, Anderson J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997.
7. Rothenberg ML, Moore MJ, Cripps MC, et al: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353, 1996.
8. Stehlin JS, Giovanella EC, Natelson EA, et al: A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 14:821-831, 1999.
9. Scher RM, Kosierowski R, Lusch C, et al: Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 13:347-354, 1996.
10. O'Reilly S, Donehower RC, Rowinsky EK, et al: A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 7:410-414, 1996.
11. Maino M, Mans DR, Di Leone L, et al: Phase II trial of a 21-day continuous infusion of topotecan in advanced pancreatic cancer: A SOAD trial (abstract). Proc Am Soc Clin Oncol 17:295, 1998.
12. Stevenson JP, Scher RM, Kosierowski R, et al: Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 34:1358-1362, 1998.